Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, Matera MG et al.. Neurology, 2009-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD). Methods This was a multicenter, prospective cohort study of 127 white patients with AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group criteria. Patients were treated with donepezil 5-10 mg/daily for 6 months. Cognitive and functional statuses were evaluated at baseline and at 6-month follow-up. Response to therapy was defined according to the National Institute for Health and Clinical Excellence criteria. Compliance and drug-related adverse events were also evaluated. The analyses identifying the CYP2D6 and APOE polymorphisms were performed in blinded fashion. Results At 6-month follow-up, 69 of 115 patients (60%) were responders and 46 patients (40%) were nonresponders to donepezil treatment. A significantly higher frequency of patients with the G allele of rs1080985 was found in nonresponders than in responders (58.7% vs 34.8%, p = 0.013). Logistic regression analysis adjusted for age, sex, Mini-Mental State Examination score at baseline, and APOE demonstrated that patients with the G allele had a significantly higher risk of poor response to donepezil treatment (odds ratio 3.431, 95% confidence interval 1.490-7.901). Conclusions The single nucleotide polymorphism rs1080985 in the CYP2D6 gene may influence the clinical efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD). The analysis of CYP2D6 genotypes may be useful in identifying subgroups of patients with AD who have different clinical responses to donepezil.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 115 participants. In this study of patients with mild to moderate Alzheimer disease, those carrying a particular CYP2D6 gene variant had a higher risk of responding poorly to donepezil. Reported effect size: 58.7%; 34.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pilotto, A., Franceschi, M., D'Onofrio, G., Bizzarro, A., Mangialasche, F., Cascavilla, L., et al. (2009). Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181b6bbe3
Vancouver
Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009. doi:10.1212/wnl.0b013e3181b6bbe3. PMID: 19738170.
BibTeX
@article{pilotto2009-19738170,
author = {Pilotto, A. and Franceschi, M. and D'Onofrio, G. and Bizzarro, A. and Mangialasche, F. and Cascavilla, L. and Paris, F. and Matera, M. G. and others},
title = {{Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease}},
journal = {Neurology},
year = {2009},
doi = {10.1212/wnl.0b013e3181b6bbe3},
pmid = {19738170},
url = {https://doi.org/10.1212/wnl.0b013e3181b6bbe3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results At 6-month follow-up, 69 of 115 patients (60%) were responders and 46 patients (40%) were nonresponders to donepezil treatment.
- A significantly higher frequency of patients with the G allele of rs1080985 was found in nonresponders than in responders (58.7% vs 34.8%, p = 0.013).
- Logistic regression analysis adjusted for age, sex, Mini-Mental State Examination score at baseline, and APOE demonstrated that patients with the G allele had a significantly higher risk of poor response to donepezil treatment (odds ratio 3.431, 95% confidence interval 1.490-7.901).
Why it matters
In this study of patients with mild to moderate Alzheimer disease, those carrying a particular CYP2D6 gene variant had a higher risk of responding poorly to donepezil. This concerns predicting response to an existing symptom treatment, not curing or preventing the disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort study
- Participants115
- Effect size58.7%; 34.8%
- Evidence strengthModerate
How this study scored 61/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 115 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 108 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.7 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 3 / 6 | Cited 7.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Davide Seripa: h-index 68 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Perugia: institution h-index 747 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19738170) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0b013e3181b6bbe3
- PubMed: 19738170
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Genetics from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.